Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...

"Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil ...

Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat mass ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...

Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, prompting the company to stop the program’s development. Neuphoria also is ...